Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05310422 · ClinicalTrials.gov registry record · Phase 3
Safety Study of Tivanisiran to Treat Dry Eye
A Phase 3 study of Dry Eye Disease, sponsored by Sylentis, S.A..
- Completed
- Registry status
- Phase 3
- Development phase
- 301
- Enrollment target
- 20
- Study locations
NCT05310422 is a Phase 3 study of Dry Eye Disease that has completed, run by Sylentis, S.A.. The registered enrollment target is 301 participants, above the 246-participant average among 33 other Dry Eye Disease trials with a reported enrollment target (22% higher). The trial reports 20 study locations across 10 states.
The verdict
NCT05310422, a Phase 3 study of Dry Eye Disease, has completed, sponsored by Sylentis, S.A..
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 301 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will examine the safety of tivanisiran sodium eye drops versus vehicle when dosed once daily for 1 year in subjects with signs and symptoms of dry eye disease (DED).
Conditions Studied
Interventions
- DRUG Tivanisiran sodium ophthalmic solution
- DRUG Vehicle ophthalmic solution
Study Locations (20)
California
- FYDES Investigative Site - Glendale
- Sylentis Investigative Site - Hemet
- Sylentis Investigative Site - Los Angeles
- Sylentis Investigative Site - Murrieta
- Sylentis Investigative Site - Newport Beach
Florida
- FYDES Investigative Site - Delray Beach
- FYDES Investigative Site - Jacksonville
- Sylentis Investigative Site - Largo
Missouri
- Sylentis Investigative Site - Kansas City
- FYDES Investigative Site - St Louis
- Sylentis Investigative Site - Washington
Arizona
- Sylentis Investigative Site - Chandler
- Sylentis Investigative Site - Phoenix
North Carolina
- Sylentis Investigative Site - Asheville
- Sylentis Investigative Site - Garner
Georgia
- Sylentis Investigative Site - Morrow
Michigan
- Sylentis Investigative Site - Fraser
New York
- Sylentis Investigative Site - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 301 participants |
| Start Date | 2022-03-24 |
| Est. Completion | 2023-10-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05310422
The ClinicalTrials.gov registry entry for NCT05310422 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 301 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 246-participant average among 33 other Dry Eye Disease trials with a reported enrollment target (22% higher). The listed sponsor is Sylentis, S.A., which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Dry Eye Disease appearing as the primary indexed condition, and to 2 interventions - of which Tivanisiran sodium ophthalmic solution is the first listed.
NCT05310422 reports 20 study locations spanning 10 distinct geographic areas - top geographies include California, Florida, Missouri.
Frequently Asked Questions
What is clinical trial NCT05310422 about?
NCT05310422 is a clinical study titled "Safety Study of Tivanisiran to Treat Dry Eye". This study will examine the safety of tivanisiran sodium eye drops versus vehicle when dosed once daily for 1 year in subjects with signs and symptoms of dry eye disease (DED).
What is the current status of trial NCT05310422?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 301 participants. The study started on 2022-03-24. Estimated completion is 2023-10-11.
What conditions does trial NCT05310422 study?
This clinical trial studies the following conditions: Dry Eye Disease.
What interventions are being tested in trial NCT05310422?
The interventions under investigation include: Tivanisiran sodium ophthalmic solution (DRUG), Vehicle ophthalmic solution (DRUG).
Who is sponsoring clinical trial NCT05310422?
This trial is sponsored by Sylentis, S.A., which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05310422 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Georgia, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dry Eye Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Clinical Study to Evaluate the Effect and Side Effect of a New Artificial Tear Formulation (ABBV-444) Compared to Refresh Optive Unit Dose in Adult Participants With Dry Eye Disease
RECRUITING · Phase 3
-
A Phase 3 Study to Evaluate AZR-MD-001 in Patients with Abnormal Meibomian Gland Function and Dry Eye Disease (DED)
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Investigate the Effect of 0.003% AR-15512 on Subjects With Dry Eye Disease
COMPLETED · Phase 3
-
Tivanisiran for Dry Eye in Subjects With Sjögren's Syndrome
COMPLETED · Phase 3
-
A Study Designed to Evaluate Tear Production
COMPLETED · Phase 3
-
ESSENCE 2: CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.